Form 4: Teladoc Health CEO Charles Divita III Acquires 507,332 Restricted Stock Units

Teladoc Health's CEO, Charles Divita III, reports the acquisition of 507,332 restricted stock units (RSUs) on March 1, 2025, according to a Form 4 filing with the SEC.

Summary

• Charles Divita III, CEO of Teladoc Health, acquired 507,332 restricted stock units (RSUs) on March 1, 2025.
• These RSUs represent a contingent right to receive one share of Teladoc Health common stock each.
• The RSUs vest over time, with one-third vesting on the first anniversary of the grant date and the remainder vesting in eight substantially equal quarterly installments thereafter.
• Following this transaction, Mr. Divita directly owns 507,332 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices and aligns management interests with shareholders. There are no immediate negative implications.

Positives

• The acquisition of restricted stock units by the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It reflects part of the executive's overall compensation package designed to incentivize performance and align interests with shareholders.

Stakeholder Impact

• Shareholders may view this as a positive sign, indicating the CEO's commitment to the company's long-term success.
• Employees may see this as a sign of stability and confidence in the company's leadership.

Key Dates